Bayer Extends CEO Bill Anderson’s Term To 2029
The Supervisory Board of Bayer AG has unanimously approved the extension of CEO Bill Anderson’s contract until March 31, 2029. Anderson, who joined Bayer in April 2023 and assumed the CEO role in June 2023, was originally set to serve until March 2026.
“Bayer is undergoing a significant transformation, and we are starting to see meaningful progress,” said Prof. Dr. Norbert Winkeljohann, Chairman of the Supervisory Board. “Bill Anderson is guiding the company in the right direction with a comprehensive turnaround plan during this critical phase. We are confident in his leadership and vision for Bayer’s future.”
Under Anderson’s leadership, Bayer is addressing five strategic priorities: strengthening its pharmaceuticals pipeline, improving profitability in crop science, implementing a leaner and more innovative operating model, reducing debt and mitigating legal risks in the U.S. These efforts are already yielding results.
“I’m honoured to continue leading Bayer through this exciting and challenging time,” said Anderson. “We are fully committed to our mission, ‘Health for all, Hunger for none,’ and I’m inspired daily by the dedication of our team. We have the right focus and the right plan to become the leanest, fastest and most innovative life science company in the world.”
Born in 1966, William N. (Bill) Anderson is a seasoned chemical engineer and executive. His career spans leadership roles at Biogen, Genentech, and Roche Pharmaceuticals, where he served as CEO before joining Bayer. He brings over three decades of experience in biotechnology and pharmaceutical innovation. Anderson is married with three adult children.
